Abstract: The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine or a pharmaceutically acceptable salt thereof, in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases, such as cognitive impairment, fatigue or a sleep disorder, for example in a mammal such as a human. The compound or a salt thereof has affinity for and is an antagonist and/or inverse agonist of the histamine H3 receptor.
Type:
Grant
Filed:
September 4, 2008
Date of Patent:
October 16, 2012
Assignee:
Glaxo Group Limited
Inventors:
Desmond John Best, Sing Yeung Mak, Barry Sidney Orlek, Geracimos Rassias, Pamela Joan Theobald
Abstract: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
Type:
Grant
Filed:
February 17, 2010
Date of Patent:
June 26, 2012
Assignee:
Glaxo Group Limited
Inventors:
Mark James Bamford, David Kenneth Dean, Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington